Top breast cancer abstracts at ASCO 2023: NATALEE and PHERGain

Breast Cancer Breakthroughs Highlights from ASCO 2023: PHERGAIN TrialПодробнее

ASCO 2023 highlights in breast cancer: NATALEE, monarchE, and PENELOPE-BПодробнее

Breast cancer at ASCO 2023: NATALEE and sequencing ADCsПодробнее

ASCO 2023 Promising Results in Breast Cancer From NATALEE and PHERGainПодробнее

Standard of care practice in Adjuvant HR+ Breast Cancer before ASCO 2023 #oncology #ASCO2023 #cancerПодробнее

Breast Cancer Breakthroughs Highlights from ASCO 2023: NATALEE TrialПодробнее

Inclusion criteria for NATALEE Trial - evaluating importance of ajuvant ribociclib #oncology #cancerПодробнее

ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-WynneПодробнее

PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemoПодробнее

SONIA, NATALEE, and Other Advances in Breast Cancer at ASCO23Подробнее

Update from ASCO 2023 - BREAST CANCER CONNECTПодробнее

What to look forward to in breast cancer at ASCO 2023Подробнее

SABCS 2023 Breast Cancer Highlights – NATALEE, MONARCH-3, INAVO120, TROPION-Breast01Подробнее

Breast Cancer ASCO 2023 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Stephanie GraffПодробнее

ASCO 2023 Breast Cancer Highlights with Prof Michael GnantПодробнее

Beyond Chemotherapy: PHERGain Clinical Trial in HER2+ Early Breast CancerПодробнее

Peter Forsyth at ASCO 2024 - Abstract 388bПодробнее

Breast Cancer Breakthroughs Episode 3: Highlights from ASCO 2023Подробнее

43. ASCO 2023 - Early Hormone Receptor Positive Breast CancerПодробнее